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Abstract
 
IL-1 is a proinflammatory cytokine that plays important roles in inflammation. However, the role
of this cytokine under physiological conditions is not known completely. In this paper, we
analyzed the role of IL-1 in maintaining body weight because IL-1 receptor antagonist–deficient
 
(IL-1Ra
 
 
 
/
 
 
 
) mice, in which excess IL-1 signaling may be induced, show a lean phenotype. Body
fat accumulation was impaired in IL-1Ra
 
 
 
/
 
 
 
 mice, but feeding behavior, expression of hypo-
thalamic factors involved in feeding control, energy expenditure, and heat production were
normal. When IL-1Ra
 
 
 
/
 
 
 
 mice were treated with monosodium glutamate (MSG), which causes
obesity in wild-type mice by ablating cells in the hypothalamic arcuate nucleus, they were
resistant to obesity, indicating that excess IL-1 signaling antagonizes the effect of MSG-sensitive
neuron deficiency. IL-1Ra
 
 
 
/
 
 
 
 mice showed decreased weight gain when they were fed the
same amount of food as wild-type mice, and lipid accumulation remained impaired even when
they were fed a high-fat diet. Interestingly, serum insulin levels and lipase activity were low in
IL-1Ra
 
 
 
/
 
 
 
 mice, and the insulin levels were low in contrast to wild-type mice after MSG
treatment. These observations suggest that IL-1 plays an important role in lipid metabolism by
regulating insulin levels and lipase activity under physiological conditions.
Key words: IL-1–deﬁcient mouse • IL-1 receptor antagonist–deﬁcient mouse • obese • skinny 
model • energy homeostasis
 
Introduction
 
IL-1 is a major mediator of inflammation. It also performs
numerous functions related to host defense mechanisms, by
regulating not only the immune system but also the neu-
ronal and endocrine systems that interface with the immune
system (1–3). IL-1 consists of two molecular species, IL-1
 
 
 
and IL-1
 
 
 
, both of which exert similar, but not completely
overlapping, biological functions through the IL-1–type I
receptor (RI). Another IL-1 receptor, the IL-1–type II
receptor (RII), has also been identified, but this receptor is
not considered to be involved in signal transduction; rather,
it is thought to play more of a regulatory role, as a “decoy.”
Another member of the IL-1 gene family, IL-1 receptor
antagonist (IL-1Ra), binds to IL-1 receptors without exerting
agonistic activity. This molecule together with IL-1RII and
the secretory forms of IL-1RI and IL-1RII are considered
to be negative regulators of IL-1 signaling, participating in
the complex regulation of IL-1 activity. IL-1 is produced by
a large variety of cells, including monocytes/macrophages,
epithelial and endothelial cells, and glial cells. IL-1Rs are
also expressed on a wide range of cells of the immune, neural,
and endocrine systems, reflecting the pleiotropic activities of
this molecule (4).
We have shown that both IL-1
 
 
 
 and IL-1
 
 
 
 are induced
in the brain of a mouse after injection with turpentine. The
stress response against turpentine injection as determined
by the development of fever and secretion of glucocorti-
coid is abolished in IL-1
 
 
 
/
 
  
 
double-deficient (IL-1
 
 
 
/
 
 
 
)
mice, suggesting that endogenous brain IL-1 plays important
roles in the stress response (5). Endogenous brain IL-1 also
plays a pivotal role in the development of anorexia and
hypothalamic cytokine expression upon administration
with LPS (6). Interestingly, IL-1 is constitutively expressed
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/
 
 
 
, IL-1
 
 
 
/
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, carbon dioxide production; VO
 
2
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in health in specific areas of the brain, including the hypo-
thalamus of humans and rodents (7, 8), and IL-1RI is also
expressed in the brain, notably in the endothelial cells of
blood vessels in the hippocampus and hypothalamus (9,
10). Because locomotive activity of IL-1
 
 
 
/
 
 
 
 
 
/
 
 
 
 mice was
lower than control mice (11) and sleep regulation was ab-
normal in IL-1
 
 
 
/
 
 
 
 mice as well as in IL-1RI
 
 
 
/
 
 
 
 mice (12,
13), brain IL-1 may play important regulatory roles in
maintaining homeostasis of the host under physiological
conditions.
We found recently that IL-1Ra gene–deficient (IL-
1Ra
 
 
 
/
 
 
 
) mice are lean and show growth retardation, sug-
gesting that IL-1 may also be involved in energy homeosta-
sis (5). In this context, IL-1 was reported to be involved in
the feeding suppression caused by leptin, which is released
from adipocytes and suppresses food intake through actions
in the hypothalamus (14–17). IL-1 promotes the release of
corticotropin releasing factor (CRF; references 18, 19),
melanocortins, and other neuropeptides (4). CRF sup-
presses feeding behavior when administered intracere-
broventricularly (20, 21). However, mice lacking both
CRF RI and RII do not show any abnormal feeding be-
havior, indicating that the absence of CRF signaling does
not accelerate feeding (22). On the other hand, excess IL-1
signaling induced by exogenously administered IL-1 or by
leptin suppresses feeding behavior through a mechanism
involving central melanocortin-3/4 receptors (MC3/4Rs;
reference 23). Furthermore, mice with knockouts of
MC3/4Rs develop mature-onset obesity (24–26), and like-
wise, mice lacking the pro-opiomelanocortin (POMC)
gene, which encodes the precursor of an endogenous ago-
nist for MC3/4Rs (
 
 
 
-melanocyte stimulating hormone),
also develop obesity (27). Thus, these receptor signals are
crucial for the feeding regulation under physiological con-
ditions. However, it is not known whether IL-1, which is
detected in the brain under physiological conditions, plays
any role in the regulation of feeding behavior through
these receptors.
IL-1 has also been suggested to be involved in peripheral
energy homeostasis through endocrine mechanisms. IL-1
 
 
 
selectively destroys the insulin-producing 
 
 
 
 cells, but not
the 
 
 
 
 cells, in vitro (28). This cytotoxic effect of IL-1 is
suggested to be mediated by the induction of inducible ni-
tric oxide synthase or prostaglandins (29–31). On the other
hand, it was reported that IL-1 acts as a hypoglycemic
agent not only in normal animals but also in alloxan-
induced diabetic and genetically diabetic mice (32) and in-
creases insulin and glucagon levels, suggesting that IL-1 has
antidiabetic effects (33). Thus, the effects of IL-1 on glu-
cose and insulin metabolism are somewhat conflicting,
probably reflecting differences in experimental conditions.
Moreover, IL-1 has been suggested to directly modulate
lipid metabolism by suppressing the activity of lipoprotein
lipase (LPL), the enzyme regulating the disposal of lipid fu-
els in the body (34, 35). IL-1 may also regulate adipocyte
function, as IL-1 inhibits adipocyte maturation and the
synthesis of fatty acid transport proteins in adipose tissue in
vitro (36, 37). These findings indicate that the IL-1/IL-
 
1Ra system may control lipid and lipoprotein metabolism
through direct actions on adipose tissues. However, it re-
mains unclear whether IL-1 is involved in energy homeo-
stasis under physiological conditions and, if so, the mecha-
nism involved is unknown.
To elucidate the role of the IL-1 system in energy ho-
meostasis in this paper, we examined feeding behavior and
peripheral metabolic changes of IL-1
 
 
 
/
 
 
 
 and IL-1Ra
 
 
 
/
 
 
 
mice under physiological conditions and in response to ma-
nipulating food intake. The results suggest that IL-1 plays
an important role in energy homeostasis under physiologi-
cal conditions, acting via a peripheral mechanism.
 
Materials and Methods
 
Animals and Diets. 
 
IL-1Ra
 
 
 
/
 
 
 
 and IL-1
 
 
 
/
 
 
 
 mice were pro-
duced by homologous recombination as described previously (5).
These mice were backcrossed to the C57BL/6J strain mice for
eight generations. Mice were housed individually from weaning at
3 wk old, and were allowed free access to chow and water, except
when described separately. Mice were kept under specific patho-
gen-free conditions in an environmentally controlled clean room
at the Center for Experimental Medicine, Institute of Medical Sci-
ence, University of Tokyo. They were housed at an ambient tem-
perature of 24
 
 
 
C and a daily cycle of 12 h light and darkness
(8:00–20:00). All experiments were performed according to the
institutional ethical guidelines for animal experiments and accord-
ing to the safety guidelines for gene manipulation experiments.
Body weight and food intake were measured in the morning,
at least twice a week, beginning from the day of weaning. 20-
wk-old mice were killed, and white adipose tissue (WAT) and
interscapular brown adipose tissue (BAT) pads were dissected
and weighed. Intraperitoneal body temperature was measured as
described previously (5). Food restriction of male mice at 8 wk
old was performed for 18 d by feeding mice 0.9 g of normal
chow each day. In food shift experiments, mice were fed a nor-
mal chow diet (fat, 5.1%; total energy, 4.18 kcal/g) or a high-fat
normocaloric diet (fat, 23.6%; total energy, 4.55 kcal/g) from 9
to 17 wk old.
For hypothalamic lesion–induced obesity, newborn mice were
administered either saline or monosodium glutamate (MSG) (4
mg/g body weight/day) i.p., from postnatal days 1 to 7 (38, 39).
Body weight and food intake were measured in the morning once
a week up to 20 wk old, the mice were killed, and serum and
WAT were collected for measuring insulin level and WAT weight.
 
Indirect Calorimetry. 
 
Amount of oxygen consumption (VO
 
2
 
)
and carbon dioxide production (VCO
 
2
 
) were simultaneously de-
termined by indirect calorimetry using Respina (IH26; NEC Sa-
nei Instruments Ltd.). Male mice at 15 wk old were housed in
separate chambers for 1 h before the experiment. 10-min mea-
surements were performed three times every 60 min during the
middle of the light cycle (11:00–17:00) under a constant air-flow
rate (200 ml/min). VO
 
2
 
 and VCO
 
2
 
 were calculated from the ox-
ygen consumption and carbon dioxide production curves using
the constant regions corresponding to resting period.
 
Fasting Experiments. 
 
To examine expression levels of neu-
ropeptides and uncoupling proteins (UCPs), age-matched mice
(6–8 wk old) were divided into three groups (
 
n
 
 
 
  
 
4 per group).
The fed group was allowed to feed ad libitum, the fasted group
was fasted for 48 h, and the refed group was allowed to feed
freely for 4 h after a 48-h fast. Mice were allowed free access to
water during these experiments. Mice were killed, and brain andT
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peripheral tissues were dissected. Northern blot analyses for total
RNA and poly (A)
 
 
 
 RNA were performed as described previ-
ously (5). 
 
 
 
-Actin was used as an internal control.
 
Probes. 
 
Probes for Northern blot hybridization were amplified
by PCR with the following specific primers, using mouse hypo-
thalamus and WAT cDNA as templates: agouti gene–related pro-
tein  sense: 5
 
 
 
-ATGCTGACTGCAATGTTGCTG-3
 
 
 
, antisense:
5
 
 
 
-CTAGGTGCGACTACAGAGGTT-3
 
 
 
; cocaine–amphetamine-
regulated transcript sense: 5
 
 
 
-ATCGAAGCGTTGCAAGAAGT-
3
 
 
 
, antisense: 5
 
 
 
-GGAATATGGGAACCGAAGGT-3
 
 
 
; melanin-
concentrating hormone sense: 5
 
 
 
-ATGGCAAAGATGACTCT-
CTCT-3
 
 
 
, antisense: 5
 
 
 
-GACTTGCCAACATGGTCGGTA-3
 
 
 
;
POMC sense: 5
 
 
 
-GCTTGCATCCGGGCTTGCAA-3
 
 
 
, anti-
sense: 5
 
 
 
-TCACTGGCCCTTCTTGTGCG-3
 
 
 
; UCP1 sense: 5
 
 
 
-
ATGGTGAACCCGACAACTTC-3
 
 
 
, antisense: 5
 
 
 
-TTATGTG-
GTACAATCCACTG-3
 
 
 
; UCP2 sense: 5
 
 
 
-ATGGTTGGTTT-
CAAGGCCAC-3
 
 
 
, antisense: 5
 
 
 
-TCAGAAAGGTGCCTCCC-
GAG-3
 
 
 
; UCP3 sense: 5
 
 
 
-ATGGTTGGACTTCAGCCCTC-3
 
 
 
,
antisense: 5
 
 
 
-TCAAAACGGAGATTCCCGCA-3
 
 
 
; resistin sense:
5
 
 
 
-AGCTGTGGGACAGGAGCTAA-3
 
 
 
, antisense: 5
 
 
 
-CCTG-
Figure 1. Body weight, food intake, and WAT weight in IL-1Ra    mice. Growth curves of male
(A) and female (B) IL-1Ra /  (closed diamonds) and wild-type mice (open squares), fed on a normal
chow ad libitum. Numbers of mice used are as follows: wild-type male (n   8) and female (n   5);
IL-1Ra /  male (n   11) and female (n   5). (C) Daily food intake of male and female IL-1Ra / 
(shaded bars) and wild-type (white bars) mice that are shown in A and B. (D) Food intake per body
weight and (E) WATs weight from the perireproductive tissues per body weight of IL-1Ra / 
(shaded bars) and wild-type (open bars) mice at 20 wk old. (F) Fat pads and various tissues from male
IL-1Ra /  mice (shaded bars, n   11) fed on a normal chow were weighed at 20 wk old, and relative
values to wild-type (n   8) tissue weight are shown. (G) Paraffin sections of WAT from epididymal
fat pads of 12-wk-old wild-type ( / ) and IL-1Ra /  ( / ) mice. Hematoxylin and eosin staining.
 200. Data are expressed as the average   SD. Epi, epididymal; Ing, inguinal; Ret, retroperitoneal;
Ad. peri-adrenal; Inter, interscapular-WAT or BAT. Statistical significance was calculated by repeated
measures ANOVAs and Tukey post hoc tests (A–C), and by Student’s t tests (D–F). *, P   0.05,
†, P   0.01 versus wild-type mice.T
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TAGAGACCGGAGGACA-3 ; adiponectin sense: 5 -GCACG-
AGGGATGCTACTGTT-3 , antisense: 5 -CCATACACCTG-
GAGCCAGAC-3 . The probe for mouse leptin was a generous gift
from K. Nakao (Kyoto University, Kyoto, Japan), and those for rat
neuropeptide Y and rat pro-orexin were from T. Sakurai (Tsukuba
University, Tsukuba, Japan).
Blood Constituents.  To analyze blood constituents, 9–10-wk-
old mice were used. Blood samples were collected by retro-
orbital puncture under anesthesia at indicated times. Blood glu-
cose levels and serum triacylglycerol (TAG), free fatty acid (FFA),
and total cholesterol (TC) levels were measured by the glucose
oxidase method (Terumo Co.) and by colorimetric assays (tri-
glyceride-L test, NEFA-C test [Wako Pure Chemical Industries
Ltd.]; Determiner TC 555 [Kyowa Medex Co.]), respectively.
Serum insulin and leptin levels were both measured by ELISA
(Seikagaku Co.).
Post-Heparin Plasma (PHP) Lipase Activity.  Male mice at 9–11
wk old were fasted from one day before the experiment, i.v.
injected with 100 U/kg body weight of heparin, and plasma
were collected 5 min later. Total and hepatic lipase activities
Figure 2. Normal expression of hypo-
thalamic peptides and adipo-cytokines after
fasting in IL-1Ra    mice. (A) 5  g poly
(A) RNAs from the hypothalamus of fed or
fasted mice (four mice for each lane) were
purified, and Northern blot hybridization
was performed with indicated probes. (B) 20
 g total RNAs from epididymal WAT
were prepared, and hybridized with indi-
cated probes. F, fed ad libitum (white bars),
A, fasted for 48 h (shaded bars).  / , wild-
type mice,  / , IL-1Ra /  mice. Auto-
radiographs are representative in three inde-
pendent experiments using at least four
animals in one group. Data are expressed as
the average   SD of all the experiments.T
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were measured using lipase activity assay kit (Progen Bio-
tech).
Glucose Tolerance Test and Insulin Tolerance Test.  For the glu-
cose tolerance test, 8–12-wk-old mice were fasted from the pre-
vious day and injected i.p. with 1.5 mg/g body weight glucose.
For the insulin tolerance test, mice were fasted for a day and in-
jected i.p. with 0.75 mU/g body weight human recombinant in-
sulin (Sigma-Aldrich). Blood samples were collected by retro-
orbital puncture.
Histological Examination.  Adipose tissue and pancreas of
9–10-wk-old mice were fixed by 10% phosphate-buffered forma-
lin and embedded in paraffin. 10- m sections were stained with
hematoxylin/eosin.
Statistical Analysis.  All values were calculated as average  
SD. Comparisons were made using the Student’s t test, one-way,
or repeated measures ANOVA, Fisher’s PLSD, or the Tukey post
hoc test, when appropriate.
Results
Growth, Food Intake, and Body Weight of IL-1Ra / 
Mice. To elucidate the role of IL-1 in body weight and en-
ergy homeostasis, we examined the growth of IL-1Ra / , IL-
1 / , and wild-type littermate mice. IL-1 /  mice showed
normal weight gain until 20 wk old, in both males and females
(reference 5 and unpublished data). Growth of IL-1Ra / 
(heterozygous) mice was also similar to wild-type mice (un-
published data). On the other hand, the body weight and daily
food intake of IL-1Ra /  male mice were lower than those of
wild-type mice at 4 wk old, and the difference in body weight
increased with age (Fig. 1, A and C). The body weight and
daily food intake of IL-1Ra /  female mice were also lower
than those of wild-type mice, although the difference was not
statistically significant (Fig. 1, B and C). However, food intake
per gram body weight was similar between IL-1Ra /  and
wild-type mice, suggesting that the reduced food intake in
mutant animals may reflect the difference in body weight (Fig.
1 D). These observations indicate that a lack of IL-1 signaling
is dispensable in the maintenance of body weight, but that ex-
cess IL-1 signaling, due to IL-1Ra deficiency, suppresses
weight gain under physiological conditions.
The fat mass per body weight of male IL-1Ra /  mice
was less than half that of wild-type mice (Fig. 1 E). Histo-
logical analysis of adipose tissue, however, revealed that ad-
ipocytes of IL-1Ra /  mice under fed conditions exhibited
normal morphology and cell volume compared with those
of wild-type mice (Fig. 1 G), suggesting that adipocyte dif-
ferentiation was not altered in IL-1Ra /  mice. Female IL-
1Ra /  mice also had significantly less fat mass than wild-
type mice (Fig. 1 E), although their body weights were
similar (Fig. 1 B). These results suggest that fat storage is
Figure 3. Impairment of energy storage in IL-1Ra    mice. Body
weight changes of age-matched wild-type (open squares, n   5) and
IL-1Ra /  (closed diamonds, n   5) male mice under food restriction
(0.9 g/day of a normal chow). Data are expressed as the average   SD.
†, P   0.01 versus wild-type mice
Figure 4. Impairment of lipid accumulation into WATs in IL-1Ra   
mice. Mice were fed with a normal chow (Normal) or a high-fat diet (HF
diet) for 8 wk. Body weight (A), epididymal WAT mass (B), and serum
TAG level (C) were compared between normal chow and high-fat diet
groups. IL-1Ra /  (shaded bars, n   5) and wild-type (white bars, n   5)
mice at the age of 17 wk were used. Data are expressed as the average  
SD. Statistical significance was determined by one-way ANOVAs and
Fischer’s PLSDs. *, P   0.05, †, P   0.01 versus wild-type mice fed with
the same chow. ‡, P   0.01 versus the same genotype mice fed with a
normal chow.T
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impaired in IL-1Ra /  mice. No difference was observed
in the weights of other tissues between IL-1Ra /  and
wild-type mice, except for the spleen, which was increased
in size in IL-1Ra /  mice (Fig. 1 F).
Expression of Energy Regulatory Factors in Peripheral Tis-
sues. We assessed the regulation of energy expenditure in
the periphery. Expression levels of UCPs (UCP1, UCP2,
and UCP3), which are involved in heat production via the
uncoupling of oxidative metabolism from ATP generation
in BAT, WAT, and skeletal muscles, were compared. We
found that UCP expression levels were normal in IL-
1Ra /  mice (unpublished data). Moreover, basal body
temperature of IL-1Ra /  mice was similar to wild-type
mice (wild-type mice: 37.8   0.6 C, n   9; IL-1Ra / 
mice: 37.5   0.7 C, n   9, P   0.29). Changes in body
temperature in response to fasting or cold stress (at 4 C for
6 h) were also similar to those of wild-type mice (unpub-
lished data). Although locomotive activity in IL-1Ra / 
mice, as assessed by the open-field test, was slightly lower
than that of wild-type mice, motor function, as evaluated
by the rota-rod test, was similar between IL-1Ra /  and
wild-type mice (unpublished data).
Furthermore, we examined energy expenditure using in-
direct calorimetry. VO2 and VCO2 of IL-1Ra /  mice
were somewhat lower compared with wild-type mice, al-
though the difference was not statistically significant (VO2
wild-type mice: 60.5   8.2 ml/kg/min, n   13; IL-1Ra / 
mice: 52.2   11.8 ml/kg/min, n   8, P   0.053; VCO2
wild-type mice: 53.2   12.3 ml/kg/min, n     13; IL-
1Ra /  mice: 44.9   15.9 ml/kg/min, n   8, P   0.094
average   SD). However, respiratory exchange ratio was
normal (wild-type mice: 0.845   0.094, n   13; IL-1Ra / 
mice: 0.853   0.148, n   8, P   0.56). These data sug-
gested that the energy expenditure in IL-1Ra /  mice is
not elevated and energy expenditure mechanisms are nor-
mal in IL-1Ra /  mice under physiological conditions.
We also examined the expression levels of the adipocyte-
derived cytokines (adipo-cytokines), adiponectin, leptin,
and resistin, which are involved in lipid and glucose metab-
olism and insulin resistance (Fig. 2 B). No differences in
expression levels of these adipo-cytokines were detected
between IL-1Ra /  and wild-type mice, suggesting that
these adipo-cytokines are not involved in the decreased en-
ergy storage in IL-1Ra /  mice.
Expression of Energy Regulatory Factors in the Central Ner-
vous System. To elucidate whether or not hypothalamic
feeding suppression mechanisms are involved in the lean
phenotype of IL-1Ra /  mice, we analyzed the expression
levels of energy regulatory factors in the brain. We examined
the expression levels of agouti gene–related protein (AGRP),
melanin-concentrating hormone (MCH), neuropeptide Y
(NPY), and orexin mRNAs as orexigenic peptides, and
cocaine–amphetamine-regulated transcript ( CART) and
POMC mRNAs as anorexigenic factors using hypothalami
from either ad libitum–fed mice or from 48-h fasted mice
(Fig. 2 A). No significant differences between wild-type and
IL-1Ra /  mRNA levels were observed, however, under
either fed or fasted conditions. These results show that the
expression of major hypothalamic factors regulating feeding
behavior is normal in IL-1Ra /  mice.
Figure 5. Decreased serum levels of insulin,
TAG, and leptin in IL-1Ra    mice. Blood glucose
(A), serum insulin (B), TAG (C), and leptin (D)
levels in body weight matched wild-type (8 wk old,
white bars) and IL-1Ra /  (15 wk old, shaded
bars) mice were measured. “Fed” samples were
collected from mice fed ad libitum 2 d before fasting.
“Fasted” samples were collected after 48 h of fasting,
and refeeding started (0 h). Data are expressed as
the average   SD, and are reproducible for three
independent experiments using at least four mice in
each genotype. Statistical significance was deter-
mined by Student’s t tests. *, P   0.05, †, P   0.01
versus wild-type mice.T
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Effect of Limited Diet on Body Weight Maintenance. We
analyzed the energy storage efficiency of these mutant mice
by measuring body weight changes in response to food re-
striction. When daily food was restricted to 0.9 g of a nor-
mal chow, the body weight of wild-type mice decreased to
two-thirds of the initial weight after 14 d and maintained
that level until 18 d (Fig. 3). Under ad libitum feeding con-
ditions, wild-type mice eat 3.2   0.4 g/day, whereas mu-
tant mice eat 2.8   0.2 g/day. Interestingly, similar body
weight loss was also observed in food-restricted IL-1Ra / 
mice, and the body weight of IL-1Ra /  mice still re-
mained significantly lower than that of wild-type mice.
These results clearly demonstrate that IL-1Ra /  mice
have defects in lipid storage even when they consume the
same amount of food as wild-type mice, which is inconsis-
tent with the notion that the lean phenotype of this mutant
mouse is not caused by a central mechanism but by periph-
eral mechanisms.
Lipid Utilization in IL-1Ra /  Mice. Next, we studied
mice that were fed a high-fat, normocaloric diet, or a nor-
mal chow for 8 wk. Body weight did not differ between
the high-fat diet group and the normal chow group, sug-
gesting that mice from both groups obtained equivalent
amounts of energy from these diets (Fig. 4 A). However,
epididymal WAT mass was significantly increased in wild-
type mice fed the high-fat diet (Fig. 4 B). In contrast, IL-
1Ra /  mice fed the high-fat diet did not gain additional
adipose mass (Fig. 4 B). Serum TAG levels in these mice
reached the same levels as in wild-type mice, although the
levels in mice fed normal diet were significantly low (Fig. 4
C). These results suggest that lipid uptake into adipose tis-
sues is impaired in IL-1Ra /  mice.
Blood Constituents in IL-1Ra /  Mice under Physiological
Conditions and after Refeeding. To examine possible in-
volvement of the endocrine system in the deficiency of
lipid uptake seen in IL-1Ra /  mice, we measured basal
levels of glucose, insulin, leptin, TAG, TC, and FFA.
Serum insulin, leptin, and TAG levels in IL-1Ra / 
male mice were significantly lower than those of wild-
type mice under fed conditions (Fig. 5). On the other
hand, levels of other blood constituents, including glu-
cose, TC, and FFA, were comparable between wild-
type and IL-1Ra /  male and female mice (TC wild-
type mice: male [92   19 mg/dl], n   5 [female, 68  
13 mg/dl, n   4]; IL-1Ra /  mice: male [85   11 mg/
dl, n   5], female [72   19 mg/dl, n   6]; FFA wild-
type mice: male [1.04   0.12 mEq/l, n   5], female
[0.91    0.03 mEq/l, n    4]; IL-1Ra /  mice: male
[0.91   0.14 mEq/l, n   5], female [1.18   0.04 mEq/l,
n   6]; average   SD).
After a 48-h fast, blood constituents were periodically
measured after refeeding, using weight-matched wild-type
and IL-1Ra /  mice, to avoid a possible confounding in-
fluence of body weight on recovery. In this experiment,
body weight and food intake were measured under fed,
fasted, and refed conditions. IL-1Ra /  mice consumed as
much food as wild-type mice during refeeding, reconfirm-
ing that appetite was not reduced in these mice (unpub-
lished data). Although glucose levels were normal, insulin,
TAG, and leptin levels in response to refeeding were al-
tered in IL-1Ra /  mice (Fig. 5). Decreased levels of se-
rum TAG and leptin in IL-1Ra /  mice persisted for 4 h
after refeeding, even though mutant mice consumed the
same amount of food as wild-type mice (Fig. 5, C and D).
Interestingly, insulin levels were significantly low in IL-
1Ra /  male mice under physiological conditions. This
trend was more clearly apparent under fasted conditions.
Upon refeeding, insulin levels in IL-1Ra /  mice were
also significantly lower than in control mice, with a delayed
peak in insulin secretion after refeeding (Fig. 5 B). Similar
results were obtained when age-matched mice were used
Figure 6. Reduction of insulin levels in IL-1Ra    mice. Insulin levels
after glucose tolerance test (A), and glucose (B) and FFA (C) levels after
insulin tolerance test in wild-type (open squares) and IL-1Ra /  (closed
diamonds) mice. Relative FFA levels are expressed as the percentage relative
to the value at time 0 (before insulin administration). Data are expressed
as the average   SD. The results are reproducible in three independent
experiments using at least four mice for each genotype. Statistical signifi-
cance was determined by Student’s t tests. *, P   0.05, †, P   0.01 versus
wild-type mice.T
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for the experiments (unpublished data). These observations
indicate that IL-1Ra deficiency affects insulin levels in the
circulation. Although we do not know whether this is due
to suppression of the insulin production or secretion, or
even acceleration of the clearance at this moment, we use
the phrase “insulin secretion” as it represents the sum of
these processes in the following sections.
The effects of IL-1Ra deficiency on insulin secretion and
insulin sensitivity were examined by glucose tolerance test
and insulin tolerance test, respectively. After administration
of glucose, the insulin response was significantly reduced in
IL-1Ra /  mice relative to wild-type mice (Fig. 6 A), al-
though blood glucose levels were not significantly different
between IL-1Ra /  and wild-type mice (unpublished
data). Furthermore, the sensitivity of blood glucose levels
to insulin was significantly increased in IL-1Ra /  mice
(Fig. 6 B), although the effect of insulin on FFA release was
similar between IL-1Ra /  and wild-type mice (Fig. 6 C).
The defect in insulin secretion in mutant mice was not due
to developmental defects, because the   cells appeared nor-
mal by hematoxylin/eosin and   cell–specific staining (un-
published data). These results indicate that IL-1Ra defi-
ciency affects lipid metabolism and insulin secretion
independently from feeding behavior.
MSG-induced Obesity and Metabolic Disorders in IL-1Ra / 
Mice. MSG treatment ablates cells in the arcuate nucleus
in the hypothalamus (ARH), which are involved in the
metabolic regulation and leptin signaling (40), and this
treatment induces maturity-onset obesity in wild-type
mice without affecting appetite (36, 39, 41). Because IL-
1RI mRNA is expressed in the ARH (9, 42), we exam-
ined the possibility that the action of IL-1 may be medi-
ated by the neurons in the ARH. As shown in Fig. 7 (A
and B), both male and female IL-1Ra /  mice showed
complete resistance to obesity in contrast to wild-type
mice. WAT weight was increased, although much less
than MSG-treated wild-type mice (Fig. 7 C). Interest-
ingly, serum insulin level was not elevated in IL-1Ra / 
mice in clear contrast to wild-type mice (Fig. 7 D). These
results indicate that excess IL-1 signaling generated in IL-
1Ra /  mice antagonizes the effect of ARH lesion.
Effect of IL-1Ra Deficiency on Lipase Activity. To further
demonstrate the effects of IL-1Ra deficiency on lipid me-
tabolism, we studied lipase activity in IL-1Ra /  mice. In
the plasma of IL-1Ra /  mice after heparin administration,
total lipase activity, but not hepatic lipase activity, was sig-
nificantly reduced compared with wild-type mice (Fig. 8).
These observations suggest that IL-1 is also involved in the
regulation of lipase activity under physiological conditions.
Discussion
In this paper, we examined the physiological role of IL-1
on feeding behavior and energy metabolism using IL-1 / 
and IL-1Ra /  mice. We found that IL-1Ra /  mice have
a defect in lipid accumulation in adipose tissue, although
IL-1 /  mice do not show any apparent abnormalities.
Thus, IL-1 signal is not necessarily required for the lipid
Figure 7. Resistance of IL-1Ra    mice to MSG-
induced obesity. Total body weights of male (A) and
female (B) control (wild-type and IL-1Ra / ) mice
(squares) and IL-1Ra /  mice (diamonds) after MSG
(closed symbols) or saline (open symbols) treatment
were measured (MSG-treated control mice: male, n   6,
female, n   8; saline-treated control mice: male, n   13,
female, n   10; MSG-treated IL-1Ra /  mice: male,
n   9, female, n   5; saline-treated IL-1Ra /  mice:
male, n   13, female, n   5). Serum insulin levels
(C) and WAT weight from epididymis (D) of male
control mice and IL-1Ra /  mice at 20 wk old after
MSG (shaded bars) or saline (white bars) treatment.
Data are expressed as the average   SD. Statistical
significance was calculated by repeated measures
ANOVAs and Tukey post hoc tests. *, P   0.05
MSG-treated IL-1Ra /  mice versus MSG-treated
wild-type mice. †, P   0.05 MSG-treated versus saline-
treated mice.T
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metabolism, but its excess signaling is harmful for the en-
ergy homeostasis of the body. The defect was more severe
in males than in females, probably reflecting hormonal dif-
ferences.
It is well-known that IL-1 is involved in fever, anorexia
(loss of appetite), and cachexia that develop during infection,
inflammation, cancer, or physical stress (4, 43). Fever and
feeding suppression caused by leptin are also mediated by hy-
pothalamic IL-1 (44). IL-1 can activate POMC neurons in
the ARH where IL-1RI mRNA is expressed (9, 42), and
the anorexic, but not pyrogenic, actions of IL-1 are medi-
ated by central MC3/4Rs (23). Recently, two groups re-
ported that cachexia was ameliorated by central MC3/4R
blockade, indicating cancer anorexia is also mediated by cen-
tral melanocortin pathway (45, 46). Furthermore, it was re-
ported that leptin was induced by LPS through induction of
IL-1 (47). Thus, it seemed likely that leanness of IL-1Ra / 
mice might be resulted from feeding suppression mediated
by the ARH–melanocortin pathway. However, our findings
suggest that the lean phenotype of IL-1Ra /  mice is not
caused by feeding suppression. This is because food intake
per gram body weight is normal, and mutant mice showed a
lean phenotype even when they were fed the same amount
as wild-type mice. IL-1Ra /  mice show normal energy ex-
penditure and heat production. Furthermore, expression lev-
els of major hypothalamic factors involved in the melanocor-
tin system are normal. Thus, we conclude that leanness of
IL-1Ra /  mice results not from feeding suppression but
from metabolic disorder in the periphery that is caused di-
rectly by excess IL-1 signaling or indirectly through central
mechanisms. IL-1 signaling under physiological conditions
may be too weak to evoke feeding suppression, and only a
large excess IL-1 signaling, such as that produced under
pathological conditions, may suppress appetite through a hy-
pothalamic mechanism.
We have shown that IL-1 /  mice do not show any ap-
parent abnormality in feeding behavior or body tempera-
ture under physiological conditions. Consistent with our
observations, it was reported that mice doubly deficient for
the CRF RI and RII, which function down-stream of IL-1
in the hypothalamus, do not show any abnormalities under
physiological conditions (22). Furthermore, IL-1Ra trans-
genic mice, with either the endogenous IL-1Ra promoter
or the glial fibrillary acidic protein promoter, did not show
any alterations in body weight (48, 49). Chronic central ad-
ministration of IL-1Ra also did not affect food intake and
weight gain in rats (50). Collectively, these observations in-
dicate that IL-1 is not necessarily required for the control of
appetite or body temperature under physiological condi-
tions, although it plays most important roles under patho-
logical conditions.
IL-1 reportedly suppresses intestinal lipid absorption and
lipid accumulation in vivo, although the mechanism has
not been completely elucidated (51). Although serum TAG
levels are low in IL-1Ra /  mice, this is not a result of de-
fects in intestinal lipid absorption, because TAG levels in
the chylomicron fraction of serum lipoproteins in IL-
1Ra /  mice are similar to those in wild-type mice (un-
published data). On the other hand, lipid accumulation is
inhibited in mutant mice, because these mice show de-
creased fat accumulation in adipose tissue even when fed a
high-fat diet, which leads to serum TAG levels similar to
wild-type mice. The ability of embryonic fibroblasts to dif-
ferentiate into mature adipocytes in vitro, however, is nor-
mal in IL-1Ra /  mice, indicating that the ability of adipo-
cyte progenitor cells to differentiate into mature adipocytes
is normal in mutant mice (unpublished data). Furthermore,
fatty acid uptake by in vitro–differentiated adipocytes from
IL-1Ra /  mice is also normal. Therefore, these observa-
tions suggest that IL-1 does not directly affect the differen-
tiation or function of adipocytes, but rather affects adipo-
cyte function by an indirect mechanism.
In this context, it is noteworthy that serum insulin levels
in IL-1Ra /  mice are significantly low under free-fed
conditions and during recovery from starvation. Impaired
insulin secretion is also observed after glucose administra-
tion. Furthermore, insulin secretion upon glucose adminis-
tration is suppressed by the administration of IL-1 in wild-
type mice (unpublished data), in agreement with previous
works (52, 53). These findings indicate that excess IL-1 sig-
naling suppresses insulin secretion from the pancreas.
Insulin is a major regulator of lipid metabolism in adipo-
cytes, and it promotes adipocyte TAG store by fostering
Figure 8. Reduced PHP lipase activity in IL-1Ra    mice. Mice were
administered 100 U/kg heparin intravenously, and plasma were collected
after 5 min (A) total lipase activity and (B) hepatic lipase activity of the
PHP from age-matched wild-type (white bars, n   8) and IL-1Ra / 
(shaded bars, n   5) male mice. Data are expressed as the average   SD.
Statistical significance was determined by Student’s t tests. *, P   0.05
versus wild-type mice.T
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the differentiation of preadipocytes, stimulating glucose
transport and TAG synthesis, and inhibiting lipolysis (54).
Insulin also increases the uptake of fatty acids derived from
circulating lipoproteins by stimulating LPL activity (55–
57) and promoting the trafficking of fatty acid transporters
in adipose tissue (58). Actually, we showed that PHP li-
pase activity is reduced in IL-1Ra /  mice. Thus, de-
creased insulin may cause reduced fat accumulation in adi-
pose tissue of IL-1Ra /  mice. It is also possible that
excess IL-1 signaling affects LPL activity resulting in the
suppression of fat accumulation.
However, normal serum glucose levels are maintained in
IL-1Ra /  mice under physiological conditions, despite
decreased insulin levels. This is because insulin sensitivity is
increased in IL-1Ra /  mice as monitored by insulin toler-
ance tests. In contrast, the sensitivity of serum FFA to insu-
lin is not increased in IL-1Ra /  mice, and the expression
of adiponectin and resistin, which are involved in the insu-
lin sensitivity of adipose tissue (59–61), are not changed.
These results indicate that the sensitivities of serum glucose
and FFAs to insulin are different, and only lipid metabolism
may be affected by the deficiency of insulin levels in IL-
1Ra /  mice.
It is known that MSG-sensitive neurons are involved in
the peripheral lipid metabolism because disruption of these
neurons causes obesity in wild-type mice, probably by acti-
vating the vagus nerves without affecting food intake (62).
It is also known that MSG treatment activates insulin secre-
tion in wild-type mice (63). In contrast, disruption of the
ARH neurons by MSG treatment did not cause obesity in
IL-1Ra /  mice. Serum insulin levels were also not in-
creased in these MSG-treated mutant mice, indicating that
excess IL-1 signaling antagonizes the effects of the ARH
neuron damage. However, it remains to be elucidated
whether IL-1 acts on the pancreas so as to antagonize the
effect of vagus nerve activation or directly suppresses vagus
nerve activation. Nonetheless, these observations support
the notion that IL-1 suppresses lipid accumulation in pe-
ripheral tissues by reducing blood insulin levels.
We reported previously that IL-1Ra /  mice on a
BALB/cA background spontaneously develop chronic in-
flammatory arthropathy resembling rheumatoid arthritis,
after weaning (64). On the C57BL/6J background, these
mutant mice, however, scarcely develop arthritis even at an
older age ( 24 wk old; reference 64). Because no IL-
1Ra /  mice on this genetic background develop arthritis
at 5 wk old, whereas the lean phenotype develops as early
as 5 wk old, leanness is not likely to be caused by autoim-
munity or inflammation.
In summary, we have shown that the lean phenotype of
IL-1Ra /  mice is not caused by feeding suppression, but
rather by impaired lipid accumulation. We showed that IL-
1Ra /  mice exhibit defects in postprandial insulin secretion
and lipid metabolism. These results indicate that the IL-1
system plays a pivotal role in maintaining insulin homeostasis
under physiological conditions. The IL-1Ra /  mouse is a
unique model for leanness and should be of use to further
investigate obesity, diabetes, and lipid metabolism disorders.
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